Condition: Lupus Nephritis · Sponsor: Otsuka Pharmaceutical Co., Ltd.
The purpose of this study is to survey the safety of LUPKYNIS in patients with lupus nephritis under actual use conditions. In addition, information on efficacy will be collected.
This description comes directly from the study's public registry record.
Pharmacovigilance Department Otsuka Pharmaceutical Co., Ltd · +81-6-6943-7722 · komaniwa.satoshi@otsuka.jp
Always discuss trial participation with your own doctor first.
| Pharmacovigilance Department | Osaka, Osaka, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07053891